On November 18, 2025, Eli Lilly announced a $2.6 billion multi-program collaboration agreement with ABL Bio to develop therapeutics using ABL Bio’s Grabody Platform for bispecific antibodies. The deal includes an upfront payment and up to $2.562 billion in milestone payments, targeting cancer and central nervous system diseases. This partnership strengthens Lilly’s position in innovative biologics and expands its reach into new therapeutic areas. The agreement is expected to enhance Lilly's portfolio and long-term growth prospects, reflecting its continued focus on advanced drug development and strategic collaborations.